INTERVENTION 1:	Intervention	0
E7389 28 Day Schedule	Intervention	1
day	UO:0000033	9-12
E7389 1.4 mg/m^2 intravenous bolus on Days 1, 8 and 15 of a 28 day cycle.	Intervention	2
day	UO:0000033	38-41
day	UO:0000033	63-66
INTERVENTION 2:	Intervention	3
E7389 21 Day Schedule	Intervention	4
day	UO:0000033	9-12
E7389 1.4 mg/m^2 intravenous bolus on Days 1 and 8 of a 21 day cycle.	Intervention	5
day	UO:0000033	38-41
day	UO:0000033	59-62
Inclusion Criteria:	Eligibility	0
Female patients with histologically or cytologically confirmed carcinoma of the breast	Eligibility	1
female	PATO:0000383	0-6
carcinoma	HP:0030731,DOID:305	63-72
breast	UBERON:0000310	80-86
Patients with advanced/metastatic disease that is not amenable to curative therapy (either surgery or radiation therapy)	Eligibility	2
disease	DOID:4,OGMS:0000031	34-41
surgery	OAE:0000067	91-98
Patients must have measurable disease by the RECIST criteria, defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan, or at least 20 mm by standard techniques; If the only measurable lesion is a lymph node, it must measure at least 20 mm in LD. If a single lesion is identified as the target lesion, a cytological or histological confirmation of breast carcinoma is required.	Eligibility	3
disease	DOID:4,OGMS:0000031	30-37
diameter	PATO:0001334	141-149
diameter	PATO:0001334	177-185
tomography	BAO:0002525	210-220
ct	BAO:0002125	222-224
lymph	UBERON:0002391	309-314
target	BAO:0003064	399-405
breast carcinoma	HP:0003002,DOID:3459	460-476
Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) and may have had prior treatment with other agents as well.	Eligibility	4
anthracycline	CHEBI:48120	47-60
taxane	CHEBI:36064	67-73
Patients must have progressed within six months of the last dose of chemotherapy, or experienced disease progression while receiving chemotherapy for advanced/metastatic disease.	Eligibility	5
disease	DOID:4,OGMS:0000031	97-104
disease	DOID:4,OGMS:0000031	170-177
Resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity	Eligibility	6
severity	HP:0012824	84-92
Age  18 years	Eligibility	7
age	PATO:0000011	0-3
Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1	Eligibility	8
group	CHEBI:24433	29-34
Life expectancy of  3 months	Eligibility	9
Adequate renal function as evidenced by serum creatinine  1.5 mg/dL or calculated creatinine clearance  50 mL/minute (min) per the Cockcroft and Gault formula	Eligibility	10
function	BAO:0003117,BFO:0000034	15-23
creatinine	CHEBI:16737	46-56
creatinine	CHEBI:16737	82-92
creatinine clearance	CMO:0000765	82-102
Adequate bone marrow function as evidenced by absolute neutrophil count (ANC)  1.5 x 10^9/L, hemoglobin  10.0 g/dL (a hemoglobin <10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion), and platelet count  100 x 10^9/L	Eligibility	11
bone marrow	UBERON:0002371	9-20
function	BAO:0003117,BFO:0000034	21-29
x	LABO:0000148	83-84
x	LABO:0000148	241-242
hemoglobin	CHEBI:35143	93-103
hemoglobin	CHEBI:35143	118-128
growth factor	BAO:0002024	186-199
platelet count	CMO:0000029	221-235
Adequate liver function as evidenced by bilirubin  1.5 mg/dL and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST)  3 times the upper limits of normal (ULN) (in the case of liver metastases  5 x ULN)	Eligibility	12
liver	UBERON:0002107	9-14
liver	UBERON:0002107	206-211
function	BAO:0003117,BFO:0000034	15-23
phosphatase	GO:0016791,BAO:0000295	74-85
alanine	CHEBI:16449	87-94
aspartate	CHEBI:29995	119-128
x	LABO:0000148	226-227
Patients willing and able to complete the FACT-B questionnaire, Analgesic Diary, Pain VAS, and the tumor-related symptomatic assessment	Eligibility	13
analgesic	CHEBI:35480	64-73
pain	HP:0012531	81-85
Patients willing and able to comply with the study protocol for the duration of the study	Eligibility	14
duration	PATO:0001309	68-76
A sample from the diagnostic biopsy (paraffin block) must be available	Eligibility	15
Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice	Eligibility	16
patient	HADO:0000008,OAE:0001817	106-113
time	PATO:0000165	142-146
Exclusion Criteria:	Eligibility	17
Patients who have received chemotherapy, radiation, hormonal therapy, or Herceptin within 2 weeks of E7389 treatment start	Eligibility	18
Radiation therapy encompassing > 10% of marrow	Eligibility	19
Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is deemed to be clinically significant by the study investigator	Eligibility	20
Prior treatment with Mitomycin C or nitrosoureas	Eligibility	21
mitomycin c	CHEBI:27504	21-32
Prior high dose chemotherapy with hematopoietic stem cell rescue in the past two years	Eligibility	22
Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen	Eligibility	23
active	PATO:0002354	83-89
Active symptomatic brain metastasis; Patients with central Nervous System (CNS) metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389	Eligibility	24
active	PATO:0002354	0-6
brain	UBERON:0000955	19-24
central nervous system	UBERON:0001017	51-73
Patients with meningeal carcinomatosis	Eligibility	25
Patients who require therapeutic anti-coagulant therapy with Warfarin or related compounds; Mini dose warfarin for catheter related thrombosis prophylaxis is permitted	Eligibility	26
warfarin	CHEBI:10033	61-69
warfarin	CHEBI:10033	102-110
thrombosis	DOID:0060903	132-142
Women who are pregnant or breast-feeding; Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.	Eligibility	27
Severe /uncontrolled intercurrent illness/infection	Eligibility	28
severe	HP:0012828	0-6
Significant cardiovascular impairment (history of congestive heart failure > NYHA grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia)	Eligibility	29
history	BFO:0000182	39-46
congestive heart failure	HP:0001635,DOID:6000	50-74
myocardial infarction	HP:0001658,DOID:5844	111-132
arrhythmia	HP:0011675	180-190
Patients with organ allografts	Eligibility	30
organ	UBERON:0000062	14-19
Patients with known positive HIV status	Eligibility	31
Patients who have had a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated  5 years previously with no subsequent evidence of recurrence	Eligibility	32
carcinoma	HP:0030731,DOID:305	53-62
skin cancer	DOID:4159	102-113
Patients with pre-existing neuropathy > Grade 1	Eligibility	33
neuropathy	DOID:870	27-37
Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative	Eligibility	34
hypersensitivity	GO:0002524,DOID:1205	16-32
halichondrin b	CHEBI:80731	36-50
halichondrin b	CHEBI:80731	58-72
Patients who participated in a prior E7389 clinical trial	Eligibility	35
Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study	Eligibility	36
disease	DOID:4,OGMS:0000031	32-39
patient	HADO:0000008,OAE:0001817	0-7
patient	HADO:0000008,OAE:0001817	108-115
Outcome Measurement:	Results	0
Overall Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST)	Results	1
rate	BAO:0080019	17-21
Defined as the percentage of subjects with CR or PR from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).	Results	2
disease	DOID:4,OGMS:0000031	86-93
disease	DOID:4,OGMS:0000031	354-361
disease	DOID:4,OGMS:0000031	407-414
tomography	BAO:0002525	150-160
ct	BAO:0002125	34-36
ct	BAO:0002125	162-164
ct	BAO:0002125	213-215
rate	BAO:0080019	228-232
diameter	PATO:0001334	331-339
diameter	PATO:0001334	389-397
progressive	HP:0003676	342-353
increase	BAO:0001251	370-378
increase	BAO:0001251	441-449
stable	HP:0031915	400-406
Time frame: Confirmed 4 to 8 weeks after first observed	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: E7389 28 Day Schedule	Results	5
day	UO:0000033	26-29
Arm/Group Description: E7389 1.4 mg/m^2 intravenous bolus on Days 1, 8 and 15 of a 28 day cycle.	Results	6
day	UO:0000033	61-64
day	UO:0000033	86-89
Overall Number of Participants Analyzed: 59	Results	7
Measure Type: Number	Results	8
Unit of Measure: percentage of participants  Complete Response:: 0	Results	9
Partial Response: 10.2	Results	10
Results 2:	Results	11
Arm/Group Title: E7389 21 Day Schedule	Results	12
day	UO:0000033	26-29
Arm/Group Description: E7389 1.4 mg/m^2 intravenous bolus on Days 1 and 8 of a 21 day cycle.	Results	13
day	UO:0000033	61-64
day	UO:0000033	82-85
Overall Number of Participants Analyzed: 28	Results	14
Measure Type: Number	Results	15
Unit of Measure: percentage of participants  Complete Response:: 0	Results	16
Partial Response: 14.3	Results	17
Adverse Events 1:	Adverse Events	0
Total: 23/70 (32.86%)	Adverse Events	1
Febrile Neutropenia2/70 (2.86%)	Adverse Events	2
Neutropenia1/70 (1.43%)	Adverse Events	3
Thrombocytopenia1/70 (1.43%)	Adverse Events	4
Inner Ear Disorder1/70 (1.43%)	Adverse Events	5
ear	UBERON:0001690	6-9
Abdominal Pain1/70 (1.43%)	Adverse Events	6
Abdominal Pain Upper1/70 (1.43%)	Adverse Events	7
abdominal pain	HP:0002027	0-14
Ascites1/70 (1.43%)	Adverse Events	8
Diarrhea1/70 (1.43%)	Adverse Events	9
Gastrointestinal Hemorrhage0/70 (0.00%)	Adverse Events	10
Nausea1/70 (1.43%)	Adverse Events	11
Small Intestinal Obstruction1/70 (1.43%)	Adverse Events	12
Vomiting1/70 (1.43%)	Adverse Events	13
Adverse Events 2:	Adverse Events	14
Total: 18/33 (54.55%)	Adverse Events	15
Febrile Neutropenia1/33 (3.03%)	Adverse Events	16
Neutropenia0/33 (0.00%)	Adverse Events	17
Thrombocytopenia0/33 (0.00%)	Adverse Events	18
Inner Ear Disorder0/33 (0.00%)	Adverse Events	19
ear	UBERON:0001690	6-9
Abdominal Pain1/33 (3.03%)	Adverse Events	20
Abdominal Pain Upper0/33 (0.00%)	Adverse Events	21
abdominal pain	HP:0002027	0-14
Ascites0/33 (0.00%)	Adverse Events	22
Diarrhea0/33 (0.00%)	Adverse Events	23
Gastrointestinal Hemorrhage1/33 (3.03%)	Adverse Events	24
Nausea0/33 (0.00%)	Adverse Events	25
Small Intestinal Obstruction0/33 (0.00%)	Adverse Events	26
Vomiting0/33 (0.00%)	Adverse Events	27
